Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study

3rd August 2020 Uncategorised 0

Subcutaneous formulation of Darzalex in combination with pomalidomide and dexamethasone meets primary endpoint

More: Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study
Source: News